Dr Janet Lee Martin

Senior Research Fellow
Medicine, Northern Clinical School
Kolling Institute of Medical Research

E25 - Royal North Shore Hospital
The University of Sydney
NSW 2006 Australia

T: +61 2 9926 8486
F: +61 2 9926 8484

W: Related website

On this page

Themes | Keywords | Publications



growth factors; Women's health; Endocrinology; Breast cancer; Cell biology


2014 | 2013 | 2011 | 2009 | 2008


  • Martin, J., de Silva, H., Lin, M., Scott, C., Baxter, R. (2014), Inhibition of insulin-like growth factor binding protein-3 signaling through sphingosine kinase 1 sensitizes triple-negative breast cancer cells to EGF receptor blockade. Molecular Cancer Therapeutics. 13(2), 316-328. [Abstract]
  • Lin, M., Marzec, K., Martin, J., Baxter, R. (2014), The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents. Oncogene. 33(1), 85-96. [Abstract]


  • Caixeiro, N., Martin, J., Scott, C. (2013), Silencing the mannose 6-phosphate/IGF-II receptor differentially affects tumorigenic properties of normal breast epithelial cells. International Journal of Cancer. 133(11), 2542-2550. [Abstract]


  • Martin, J., Baxter, R. (2011), Signalling pathways of insulin-like growth factors (IGFs) and IGF binding protein-3. Growth factors (Chur, Switzerland). 29(6), 235-44. [Abstract]
  • Lin, W., Martin, J., Marsh, D., Jack, M., Baxter, R. (2011), Involvement of insulin-like growth factor binding protein-3 in the effects of the histone deacetylase inhibitor MS-275 in hepatoma cells. The Journal of biological chemistry. 286(34), 29540-7. [Abstract]


  • Martin, J., Lin, M., McGowan, E., Baxter, R. (2009), Potentiation of growth factor signaling by insulin-like growth factor binding protein-3 in breast epithelial cells requires sphingosine kinase activity. The Journal of biological chemistry. 284(38), 25542-52. [Abstract]


  • Marsh, D., Trahair, T., Martin, J., Chee, W., Walker, J., Kirk, E., Baxter, R., Marshall, G. (2008), Rapamycin treatment for a child with germline PTEN mutation. Nature clinical practice. Oncology. 5(6), 357-61. [Abstract]